This event is for Professional Community member only.
For more information about the OPEN membership plans, please see here.
Psycholytic Therapy: Lessons from Low-Moderate Dose Psilocybin Research
Sara Oke (Lead Psychedelic Research Therapist in Psychopharmacology)
Thursday 17 July, 2025 7PM CEST (5PM GMT, 1PM ET, 10AM PT)
Online via Zoom
Add to Calendar
Research studies focused on high-dose psychedelic use dominate the psychedelic field. Psycholytic therapy, a form of psychedelic-assisted psychotherapy that uses low to moderate doses of psychedelics such as psilocybin, has gained renewed interest in mental health treatment. A study on low to moderate dose psilocybin for obsessive-compulsive disorder (OCD) has provided valuable insights into the potential therapeutic benefits and mechanisms of change in psycholytic therapy. This lecture explores themes from participant experiences in a psilocybin trial and highlights the core principles of a psychological support model.
What you will learn
- What is psycholytic therapy? An introduction to its history, foundations, and current resurgence in psychedelic-assisted psychotherapy.
- How psycholytic therapy both complements and differs from high-dose, peak experience approaches in psychedelic research and practice.
- Key therapeutic themes emerging from participant experiences in low to moderate dose psilocybin sessions—and what they reveal about pathways to change.
Who is this for?
This session is designed for professionals working in or entering the field of psychedelic therapy, including:
- Therapists, clinicians, and mental health practitioners interested in integrating psychedelic-assisted therapy into their practice.
- Researchers seeking a nuanced understanding of different dosing paradigms and therapeutic frameworks.
- Practitioners curious about the evolving clinical applications of psilocybin beyond peak-dose models.
- Professionals in the psychedelic field interested in ethical, supportive, and culturally attuned approaches to psychedelic care.
